Immuneering Corp, often identified by its stock symbol IMRX, is a pioneering bio-pharmaceutical company that specializes in disease treatment. Established in 2008, the US-based organization uses its unique bioinformatics and data analysis capabilities to discover and develop drugs that are more effective and safer.
Having spent over a decade working with 10 out of the top 20 largest pharmaceutical companies, Immuneering has gradually earned an impression of being an expert in the field. This has added to the robustness of its proprietary Disease Cancelling Technology, which is utilized in its drug development pipeline.
Immuneering Corp.’s novel approach allows it to decode complex biological information. Their Disease Cancelling Technology, for instance, reverses the gene expression signals of disease to improve the therapeutic aspect of treatment. This approach has been used across a wide variety of diseases including cancer, neurological disorders, and autoimmune diseases.
The company is currently focusing on oncology and is making significant strides in this area. Its two lead oncology drug candidates, IMR-687 and IMR-907, are designed to treat the sickle cell disease and leukemia, respectively. Immuneering is using its notable strides in medical research and technology to revolutionize cancer therapy, specifically targeting the mTOR pathway, a crucial driver of several notorious cancers.
Despite being a relatively young company, Immuneering Corp has achieved numerous milestones in the bio-pharmaceutical realm. Its distinctive approach to disease understanding and treatment has not only challenged traditional pharmaceutical methods but has also shown the enormous potential for disruptive change in the treatment of chronic illnesses.
Immuneering Corp's enduring commitment to battling illnesses via pioneering technological advancements has made it a beacon within the bio-pharmaceutical industry. While the company continues to forge its path in disease cancellation, its dedication to improving the lives of patients worldwide is made abundantly clear.
With a state-of-the-art bioinformatic platform and a robust drug pipeline, Immuneering Corp is undoubtedly a rising star in the pharmaceutical sector. The company’s mission is to transform cancer treatment and deliver safe and effective options to patients in need. Given the potential of their innovative technology, Immuneering Corp is well-positioned to make significant contributions and advancements in the drug development industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Immuneering Corporation announced grants of inducement awards to its new Chief Financial Officer, Andrew Gengos, and a non-executive employee. Mr. Gengos received an option to purchase 650,000 shares of common stock with a per-share exercise price of $4.78, vesting over four years. An additional non-executive employee received an option to purchase 32,400 shares of common stock, vesting over four years.
Immuneering (NASDAQ:IMRX) is an unprofitable company with a strong cash runway of over three years, possessing US$157m in cash against an annual burn of US$50m as of March 2026. The company has reduced its cash burn by 7% over the last year, indicating steady business development without significant spending increases. With a market capitalization of US$325m, Immuneering could easily raise more capital if needed, though this would result in some shareholder dilution.
Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, where shareholders elected Peter Feinberg and Laurie B. Keating as Class II directors and ratified RSM US LLP as the independent auditor for the 2026 fiscal year. This decision by 68.8% of outstanding shares demonstrates continued support for the company's leadership and strategic direction. Immuneering (IMRX) also received a "Buy" rating from analysts with an $11.00 price target, despite Spark's AI Analyst giving it a "Neutral" score due to financial fundamentals.